Clinical Trial Update: Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis [Phase 1, Phase 2]

View source ↗

Summary

Nexcella Inc. is conducting a Phase 1/2 clinical trial of the CAR-T therapy NXC-201 to treat AL amyloidosis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• NXC-201 CAR-T

Snippet

Sponsor: Nexcella Inc. | Conditions: Light Chain (AL) Amyloidosis | Phase 1, Phase 2 | Status: RECRUITING